Akari Therapeutics, Plc

Reminder: Tomorrow at 1pm PT, Akari's Miles Nunn will present at the conference taking place in Seattle, Washington. Learn more: https://bit.ly/49ENCMO

Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics. https://bit.ly/3UBPDF7

Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics - Akari Therapeutics BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced leadership changes, including the appointment of experienced life sciences entrepreneur Samir R...

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity. https://bit.ly/3Qrz0JE

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity - Akari Therapeutics BOSTON and PLEASANTON, Calif., May 01, 2024 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX, “Akari”) and Peak Bio Inc. (OTC: PKBO, “Peak”) today announced completion of a joint portfolio prioritization review pursuant to which the combined entity, following completion of the prev...

Join Chief Scientific Officer, Miles Nunn for Akari's poster presentation at the upcoming conference on Sunday, May 5th, from 1pm to 2:45pm PT. Find details: https://bit.ly/49ENCMO

Attending the Association for Research in Vision and Ophthalmology 2024 Annual Meeting? Akari CSO Miles Nunn is presenting new pre-clinical data on investigational long-acting PAS-nomacopan including drug effect on electroretinography (ERG) testing in a blue light model on May 5th, at 1pm PT. More information can be found here: https://bit.ly/49ENCMO

Join us today in supporting and the 300 million people worldwide who have rare diseases. Akari is developing advanced therapies for and diseases, including the rare condition . https://bit.ly/3uVvbF6

(GA) patients face risks to sight from both the condition and CNV, a risk associated with approved GA treatments. Learn how PAS-nomacopan with C5+LTB4 inhibition may help address both risks: https://bit.ly/3Rlji3U

February is ! (GA) is a progressive, sight-threatening condition affecting 5 million people worldwide. Learn about Akari’s pre-clinical research of long-acting PAS-nomacopan as a potential treatment for GA: https://bit.ly/3Rlji3U

Long-acting PAS-nomacopan is being developed as a treatment with potential for fewer intravitreal injections and reduced risk of sight-threatening choroidal neovascularization (CNV) associated with complement-only inhibitors approved for GA treatment. Learn more:

PAS-NOMACOPAN IN GA - Akari Therapeutics Akari is conducting a pre-clinical research program to develop long-acting PAS-nomacopan with the potential for three key benefits: complement inhibition, fewer doses, and leukotriene B4 (LTB4) inhibition to address the risks of choroidal neovascularization (CNV) associated complement-only inhibi...

TMA is a rare and serious complication of HSCT (stem cell transplant) characterized by complement activation, inflammation, tissue hypoxia, and blood clots. It can lead to progressive organ damage and death. There are no approved treatment options in the U.S. and Europe. https://bit.ly/46ADwLf

Akari is developing novel advanced therapies for and . Akari’s investigational nomacopan is a bispecific recombinant inhibitor of complement C5 and leukotriene B4 (LTB4). Learn more: https://bit.ly/3Mo5lza

COMPANY OVERVIEW - Akari Therapeutics Akari Therapeutics, Plc (NASDAQ: AKTX) is a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Akari’s lead asset, investigational nomacopan, is a bispecific recominant inhibitor of complement C5 and leukotriene B4 (LTB4) activity.  Novel C5...

Long-acting PAS-nomacopan is being developed as a treatment with potential for fewer intravitreal injections and reduced risk of sight-threatening choroidal neovascularization (CNV) associated with complement-only inhibitors approved for GA treatment. Learn more:

PAS-NOMACOPAN IN GA - Akari Therapeutics Akari is conducting a pre-clinical research program to develop long-acting PAS-nomacopan with the potential for three key benefits: complement inhibition, fewer doses, and leukotriene B4 (LTB4) inhibition to address the risks of choroidal neovascularization (CNV) associated complement-only inhibi...

Potentially lifesaving medicine from ticks? Hear CEO Rachelle Jacques discuss how Akari engineered , a recombinant protein derived from ticks, and scaled manufacturing for clinical trials and beyond. Listen here: https://bit.ly/3MRvNl1

Tick-Derived Therapeutic Molecules With Akari Therapeutics' Rachelle Jacques The emerging biotech Akari Therapeutics thinks there's a broad range of medicinal value in proteins found in—wait for it—the saliva of ticks. Akari has painstakingly developed a recombinant version of one such tick saliva-derived protein, called nomacopan, and put it to work...

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing.

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing - Akari Therapeutics BOSTON and LONDON, January 2, 2024 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that it closed a private placement financing with existing investors, Akar...

Akari’s pre-clinical program is developing long-acting PAS-nomacopan for the treatment of (GA) with the potential for three key benefits: complement inhibition, fewer doses, and leukotriene B4 (LTB4) inhibition to address risk of choroidal neovascularization (CNV) associated with complement-only inhibitors approved for GA treatment.

PAS-NOMACOPAN IN GA - Akari Therapeutics Akari is conducting a pre-clinical research program to develop long-acting PAS-nomacopan with the potential for three key benefits: complement inhibition, fewer doses, and leukotriene B4 (LTB4) inhibition to address the risks of choroidal neovascularization (CNV) associated complement-only inhibi...

Akari Chief Scientific Officer Dr. Miles Nunn hypothesized that parasites’ interactions with their hosts could offer the key to breakthroughs in and disease therapies and discovered in ticks. For more information, visit: https://bit.ly/4146rWP

Akari’s pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric HSCT-TMA, as well as a clinical program developing nomacopan for adult HSCT-TMA and pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). For more: https://bit.ly/3FOByfb

In a recent presentation, Akari CEO Rachelle Jacques highlights the potential of our lead asset, investigational nomacopan, currently in development for both pediatric and adult hematopoietic stem cell transplant-related thrombotic microangiopathy. Learn more: https://bit.ly/3FFRvEA

Akari Therapeutics, plc (NASDAQ: AKTX) Akari Therapeutics, plc (NASDAQ: AKTX) is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases.Keynote speaker: Rac...